Postconditioning: From the bench to bedside

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 16, Issue 2, 2011, Pages 117-130

  Cour, Martin ^a,b,c   Gomez, Ludovic ^a   Mewton, Nathan ^a   Ovize, Michel ^a,c   Argaud, Laurent ^a,b,c  

^a INSERM   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c UNIVERSITÉ LYON 1   (France)

Author keywords

Cardioprotection; Cyclosporine A; Mitochondrial permeability transition; Postconditioning; Reperfusion injury

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALCIUM ION; CREATINE KINASE; CYCLOSPORIN A; CYCLOSPORIN A [4 N METHYLISOLEUCINE]; GLYCOGEN SYNTHASE KINASE 3BETA; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; SODIUM PROTON EXCHANGE PROTEIN;

CELL DEATH; CELL PH; CELL ULTRASTRUCTURE; DISEASE SEVERITY; DRUG TARGETING; HEART INFARCTION SIZE; HEART MITOCHONDRION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; MITOCHONDRIAL PERMEABILITY; MYOCARDIAL ISCHEMIC POSTCONDITIONING; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPERFUSION INJURY; RESUSCITATION; REVIEW; SIGNAL TRANSDUCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STUNNED HEART MUSCLE;

EID: 79960168096     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248410383174     Document Type: Review

References (95)

1. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74(5): 1124-1136. (Pubitemid 17174962)
2. Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev. 2003; 83(4):1113-1151. (Pubitemid 37222269)
3. Thornton JD, Liu GS, Olsson RA, Downey JM. Intravenous pretreatment with Al selective adenosine analogues protects the heart against infarction. Circulation. 1992;85(2):659-665.
4. Wall TM, Sheehy R, Hartman JC. Role of bradykinin in myocardial preconditioning. J Pharm Exp Titer. 1994;270(2):681-689. (Pubitemid 24271382)
5. Shultz JE, Hsu AK, Gross GJ. Morphine mimics the cardioprotective effect of ischemic preconditioning via a glibenclamide-sensitive mechanism in the rat heart. Circ Res. 1996;78(6):1100-1104.
6. Hausenloy DJ, Tsang A, Mocanu M, Yellon DM. Ischemic preconditioning protects by activating pro-survival kinases at reperfusion. Am J Physiol Heart Circ Physiol. 2005;288(2):H971-H976. (Pubitemid 40139686)
7. Ytrehus K, Liu Y, Downey JM. Preconditioning protects ischemic rabbit heart by protein kinase C activation. Am J Physiol. 1994; 266(3 pt 2):H1145-H1152. (Pubitemid 24121336)
8. Murphy E. Primary and secondary signaling pathways in early preconditioning that converge on the mitochondria to produce cardioprotection. Circ Res. 2004;94(1):7-16. (Pubitemid 38064093)
9. Argaud L, Gateau-Roesch O, Chalabreysse L, et al. Preconditioning delays Ca2+-induced mitochondrial permeability transition pore. Cardiovasc Res. 2004;61:115-122. (Pubitemid 38056687)
10. Argaud L, Loufouat J, Gateau-Roesch O, Gomez L, Robert D, Ovize M. Persistant inhibition of mitochondrial permeability transition pore by preconditioning in the first hours of reperfusion. Shock. 2008;30(5):552-556.
11. Argaud L, Prigent AF, Chalabreysse L, Loufouat J, Lagarde M, Ovize M. Ceramide in the antiapoptotic effect of ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2004;286(1): H246-H251. (Pubitemid 38049486)
12. Yellon D, Alkhulaifi AM, Pugsley WB. Preconditioning the human myocardium. Lancet. 1993;342(8866):276-277. (Pubitemid 23224422)
13. Walsh SR, Tang TY, Kullar P, Jenkins DP, Dutka DP, Gaunt ME. Ischaemic preconditioning during cardiac surgery: systematic review and meta-analysis of perioperative outcomes in randomised clinical trials. Eur J Cardiothorac Surg. 2008;34(5):985-994.
14. Hausenloy DJ, Mwamure PK, Venugopal, et al. Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial. Lancet. 2007;370(9587):575-579. (Pubitemid 47247853)
15. Kloner RA, Shook T, Przyklenk K, et al. Previous angina alters inhospital outcome in TIMI 4. A clinical correlate to preconditioning? Circulation. 1995;91(1):37-45.
16. Laskey WK. Beneficial impact of preconditioning during PTCA on creatine kinase release. Circulation. 1999;99(16):2085-2089. (Pubitemid 29196790)
17. Argaud L, Rioufol G, Liévre M, et al. Preconditioning during coronary angioplasty: no influence of collateral perfusion on the size of the area at risk. Eur Heart J. 2004;25(22):2019-2025. (Pubitemid 39486021)
18. Botker HE, Kharbanda R, Schmidt MR, et al. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomized trial. Lancet. 2010; 375(9719):727-734.
19. Rezkalla SH, Kloner RA. Preconditioning in humans. Heart Fail Rev. 2007;12(3-4):201-206. (Pubitemid 350176693)
20. Zhao ZQ, Corvera JS, Halkos ME, et al. Inhibition of myocardial injury by ischemic postconditioning: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2003;285(2): H579-H588. (Pubitemid 36885888)
21. Piper HM, Abdallah Y, Schafer C. The first minutes of reperfusion: a window of opportunity for cardioprotection. Cardiovasc Res. 2004;61(3):365-371. (Pubitemid 38210144)
22. Kin H, Zhao ZQ, Sun HY, et al. Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion. Cardiovasc Res. 2004;62(1):74-85. (Pubitemid 38326813)
23. Jennings RB, Reimer KA. The cell biology of acute myocardial ischemia. Annu Rev Med. 1991;42:225-246.
24. Garcia Dorado D, Theroux P, Duran JM, et al. Selective inhibition of the contractile apparatus. A new approach to modification of infarct size, infarct composition, and infarct geometry during coronary artery occlusion and reperfusion. Circulation. 1992; 85(3):1160-1174.
25. Piper HM, Meuter K, Schafer C. Cellular mechanisms ofischemiareperfusion injury. Ann Thorac Surg. 2003;75(2):644-648.
26. Crompton M. Mitochondrial intermembrane junctional complexes and their role in cell death. J Physiol. 2000;529(pt 1):11-21.
27. Shen AC, Jennings RB. Kinetics of calcium accumulation in acute myocardial ischemic injury. Am J Pathol. 1972;67(3):441-452.
28. Gateau-Roesch O, Argaud L, Ovize M. Mitochondrial permeability transition and postconditioning. Cardiovasc Res. 2006;70(2): 264-273.
29. McGovern PG, Pankow JS, Shahar E, et al. Recent trials in acute coronary disease: mortality, morbidity, medical care and risk factors: the Minnesota Heart Survey Investigators. N Engl J Med. 1996;334(14):884-890. (Pubitemid 26107346)
30. Braunwald E, Kloner RA. Myocardial reperfusion: a doubleedged sword? J Clin Invest. 1985;76(5):1713-1719.
31. Kloner RA, Dow J, Bhandari A. Postconditioning markedly attenuates ventricular arrhythmias after ischemia-reperfusion. J Cardiovasc Pharmacol Ther. 2006;11(1):55-63.
32. Piper HM, Garcia-Dorado D, Ovize M. A fresh look at reperfusion injury. Cardiovasc Res. 1998;38(2):291-300. (Pubitemid 28294147)
33. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007;357(11):1121-1135.
34. Paillard M, Gomez L, Augeul L, Loufouat J, Lesnefsky EJ, Ovize M. Postconditioning inhibits mPTP opening independent of oxydative phosphorylation and membrane potential. J Mol Cell Cardiol. 2009;46(6):902-909.
35. Hausenloy DJ, Tsang A, Yellon DM. The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc Med. 2005; 15(2):69-75. (Pubitemid 40693390)
36. Sun HY, Wang NP, Kerendi F, et al. Hypoxic postconditioning reduces cardiomyocyte loss by inhibiting ROS generation and intracellular Ca2+ overload. Am J Physiol Heart Circ Physiol. 2005;288(4):H1900-H1908. (Pubitemid 40418019)
37. Bopassa JC, Ferrera R, Gateau-Roesch O, Couture-Lepetit E, Ovize M. PI3-kinase regulates the mitochondrial transition pore in controlled reperfusion and postconditioning. Cardiovasc Res. 2006;69(1):178-185. (Pubitemid 41814821)
38. Tsang A, Hausenloy DJ, Mocanu MM, Yellon DM. Postconditioning: a form of "modified reperfusion" protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ Res. 2004;95(3):230-232. (Pubitemid 39056282)
39. Yang XM, Proctor JB, Cui L, Krieg T, Downey JM, Cohen MV. Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways. J Am Coll Cardiol. 2004;44(5): 1103-1110. (Pubitemid 39165147)
40. Philipp S, Yang XM, Cui L, Davis AM, Downey JM, Cohen MV. Postconditioning protects rabbit hearts through a protein kinase C-adenosine A2b receptor cascade. Cardiovasc Res. 2006;70(2): 308-314.
41. Peart JN, Headrick JP. Adenosinergic cardioprotection: multiple receptors, multiple pathways. Pharmacol Ther. 2007; 114(2): 208-221. (Pubitemid 46561536)
42. Bell RM, Yellon DM. Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: the role of the PI3K, Akt and eNOS. J Mol Cell Cardiol. 2003;35(2):185-193. (Pubitemid 36269192)
43. Penna C, Mancardi D, Rastaldo R, Losano G, Pagliaro P. Intermittent activation of bradikinin B2 receptors and mitochondrial KATP channels trigger cardiac postconditioning through redox signaling. Cardiovasc Res. 2007;75(1):168-177. (Pubitemid 46881061)
44. Gross ER, Hsu AK, Gross GJ. Opioid-induced cardioprotection occurs via glycogen synthase kinase beta inhibition during reperfusion in intact hearts. Circ Res. 2004;94(7):960-966. (Pubitemid 38490074)
45. Gomez L, Paillard M, Thibault H, Derumeaux G, Ovize M. Inhibition of GSK3b by postconditioning is required to prevent opening of the mitochondrial permeability transition pore during reperfusion. Circulation. 2008;117(21):2761-2768. (Pubitemid 351770456)
46. Cohen MV, Yang XM, Downey JM. The pH hypothesis of postconditioning: staccato reperfusion reintroduces oxygen and perpetuates myocardial acidosis. Circulation. 2007;115(14): 1895-1903. (Pubitemid 46598903)
47. Inserte J, Barba I, Hernando V, Garcia-Dorado D. Delayed recovery of intracellular acidosis during reperfusion prevents calpain activation and determines protection in postconditioned myocardium. Cardiovasc Res. 2009;81 (1): 116-122.
48. Rodriguez-Sinovas A, Abdallah Y, Piper HM, Garcia-Dorado D. Reperfusion injury as a therapeutic challenge in patients with acute myocardial infarction. Heart Fail Rev. 2007;12(3-4): 207-216. (Pubitemid 350176694)
49. Argaud L, Gateau-Roesch O, Augeul L, et al. Increased mitochondrial calcium coexists with decreased reperfusion injury in postconditioned (but not preconditioned) hearts. Am J Physiol Heart Circ Physiol. 2008;294(1):H386-H391.
50. Weiss JN, Korge P, Honda HM, Ping P. Role of the mitochondrial permeability transition in myocardial disease. Circ Res. 2003; 93(4):292-301. (Pubitemid 37048241)
51. Kroemer G, Dallaporta B, Resche-Rigon M. The mitochondrial death/life regulator in apoptosis and necrosis. Ann Rev Physiol. 1998;60:619-642. (Pubitemid 28157889)
52. Crompton M. Mitochondrial intermembrane junctional complexes and their role in cell death. J Physiol. 2000;529(pt 1): 11-21.
53. Bernardi P, Petronelli V. The permeability transition pore as a mitochondrial calcium release channel: a critical appraisal. J Bioenerg Biomembr. 1996;28(2):129-136.
54. Kokoszka JE, Waymire KG, Levy SE, et al. The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore. Nature. 2004;427:461-465. (Pubitemid 38168501)
55. Baines CP, Kaiser RA, Sheiko T, et al. Voltage-dependent anion channels are dispensable for mitochondrial-dependent cell death. Nat Cell Biol. 2007;9(5):550-555. (Pubitemid 46696536)
56. Basso E, Fante L, Fowlkes J, Petroilli V, Forte MA, Bernardi P. Properties of the permeability transition pore in mitochondria devoid of Cyclophilin D. J Biol Chem. 2005;280(19): 18558-18561. (Pubitemid 41379552)
57. Woodfield K, Ruck A, Brdiczka D, Halestrap AP. Direct demonstration of a specific interaction between cyclophilin-D and the adenine nucleotide translocase confirms their role in the mitochondrial permeability transition. Biochem J. 1998;336(pt 2): 287-290. (Pubitemid 28564382)
58. Fournier N, Ducet G, Crevat A. Action of cyclosporine on mitochondrial fluxes. J Bioenerg Biomembr. 1987;19(3):297-303.
59. Halestrap AP, Clarke SJ, Javadov SA. Mitochondrial permeability transition pore opening during myocardial reperfusion - a target for cardioprotection. Cardiovasc Res. 2004;61(3):372-385. (Pubitemid 38210145)
60. Griffiths EJ, Halestrap AP. Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochem J. 1995;307(pt 1):93-98.
61. Di Lisa F, Menabo R, Canton M, Barile M, Bernardi P. Opening of the mitochondrial permeability transition pore causes depletion of mitochondrial and cytosolic NAD+ and is a causative event in the death of myocytes in postischemic reperfusion of the heart. J Biol Chem. 2001;276(4):2571-2575.
62. Griffiths EJ, Halestrap AP. Protection by Cyclosporin A of ischemia reperfusion induced damage in isolated rat hearts. J Mol Cell Cardiol. 1993;25(12):1461-1469. (Pubitemid 24049454)
63. Leducq N, Delmas-Beauvieux MC, Bourdel-Marchasson I, et al. Mitochondrial and energetic dysfunctions of the liver during normothermic reperfusion: protective effect of cyclosporine and role of the mitochondrial permeability transition pore. Transplant Proc. 2000;32(2):479-480. (Pubitemid 30133331)
64. Bernardi P, Krauskopf A, Basso E, et al. The mitochondrial permeability transition from in vitro artifact to disease target. FEBS J. 2006;273(10):2077-2099.
65. Hausenloy DJ, Maddock HL, Baxter GF, Yellon DM. Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? Cardiovasc Res. 2002; 55(3):534-543. (Pubitemid 34874948)
66. Argaud L, Gateau-Roesch O, Muntean D, et al. Specific inhibition of the mitochondrial permeability transition prevents lethal reperfusion injury. J Mol Cell Cardiol. 2005;38(2):367-374. (Pubitemid 40215206)
67. Argaud L, Gateau-Roesch O, Raisky O, Loufouat J, Robert D, Ovize M. Postconditioning inhibits mitochondrial permeability transition. Circulation. 2005;111 (2): 194-197. (Pubitemid 40139731)
68. Argaud L, Gomez L, Gateau-Roesch O, et al. Trimetazidine inhibits mitochondrial permeability transition pore opening and prevents lethal ischemia-reperfusion injury. J Mol Cell Cardiol. 2005;39(6):893-899. (Pubitemid 41572322)
69. Argaud L, Carrier O, Loufouat J, et al. Second generation sulfonylureas preserve inhibition of mitochondrial permeability transition by the mitochondrial K+(ATP) opener nicorandil in experimental myocardial infarction. Shock. 2009;32(3): 247-252.
70. Piriou V, Chiari P, Gateau-Roesch O, et al. Desflurane-induced preconditioning alters calcium-induced mitochondrial permeability transition. Anesthesiology. 2004;100(3):581-588. (Pubitemid 38268876)
71. Ge ZD, Pravdic D, Bienengraeber M, et al. Isoflurane postconditioning protects against reperfusion injury by preventing mitochondrial permeability transition by an endothelial nitric oxide synthase-dependent mechanism. Anesthesiology. 2010;112(1): 73-85.
72. Baines CP, Kaiser RA, Purcell NH, et al. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature. 2005;434(7033):658-662. (Pubitemid 40488559)
73. Nakagawa T, Shimizu S, Wanatabe T, et al. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature. 2005; 434(7033):652-658. (Pubitemid 40488558)
74. Reimer KA, Jennings RB. The "wavefront phenomenon" of ischemic cell death. Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral blood flow. Lab Invest. 1979;40(6):633-644. (Pubitemid 9191795)
75. Staat P, Rioufol G, Piot C, et al. Postconditioning the human heart. Circulation. 2005;112:2143-2148. (Pubitemid 41475808)
76. Feild BJ, Russell RO Jr, Dowling JT, Rackley CE. Regional left ventricular performance in the year following myocardial infarction. Circulation. 1972;46(4):679-689.
77. Aletras AH, Tilak GS, Natanzon A, et al. Retrospective determination of the area at risk for reperfused acute myocardial infarction with T2-weighted cardiac magnetic resonance imaging. Circulation .2006;113(15):1865-1870.
78. Sivaraman V, Mudalagiri NR, Di Salvo C, et al. Postconditioning protects human atrial muscle through the activation of the RISK pathway. Basic Res Cardiol. 2007;102(5):453-459. (Pubitemid 47278818)
79. Laskey WK. Brief repetitive balloon occlusions enhance reperfusion during percutaneous coronary intervention for acute myocardial intervention: a pilot study. Catheter Cardiovasc Jnterv. 2005; 65(3):361-367. (Pubitemid 40898179)
80. Thibault H, Piot C, Staat P, et al. Long-term benefit of postconditioning. Circulation. 2008;117(8):1037-1044.
81. Lonborg J, Kelbaek H, Vejlstrup N, et al. Cardioprotective effects of ischemic postconditioning in patients with primary percutaneous coronary intervention, evaluated by magnetic resonnance. Circ Cardiovasc Jnterv. 2010;3(1):34-41.
82. Knight CJ. Filters, extractors and other devices in acute myocardial infarction. Heart. 2010;96(10): 190-195.
83. Svilaas T, Vlaar PJ, van der Horst IC, et al. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med. 2008;358(6):557-567. (Pubitemid 351214283)
84. Shanmuganathan S, Hausenloy DJ, Duchen MR, Yellon DM. Mitochondrial permeability transition pore as a target for cardioprotection in the human heart. Am J Physiol Heart Circ Physiol. 2005;289(1):H237-H242. (Pubitemid 40934105)
85. Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med. 2008; 359(5):473-481.
86. Mewton N, Croisille P, Gahide G, et al. Effect of cyclosporine on left ventricular remodeling after reperfused myocardial infarction. J Am Coll Cardiol. 2010;55(12): 1200-1205.
87. De Rougemont O, Lahmann K, Clavien PA. Preconditioning, organ preservation, and postconditioning to prevent ischemia-reperfusion injury to the liver. Jiver Transpl. 2009;15(10):1172-1182.
88. Szwarc I, Soullier S, Gayrard N, Mejean C, Mourad G, Argiles A. Ischemic postconditioning prevents ischemic acute renal failure. Transplant Proc. 2007;39(8):2554-2556. (Pubitemid 47588390)
89. Oka N, Wang L, Mi W, Caldarone CA. Inhibition of mitochondrial remodeeling by cyclosporine A preserves myocardial performance in a neonatal rabbit model of cardioplegic arrest. J Thorac Cardiovasc Surg. 2008;135(3):585-93. (Pubitemid 351329328)
90. Mbye LH, Singh IN, Carrico KM, Saatman KE, Hall ED. Comparative neuroprotective effects of cyclosporin A and NIM811, a nonimmunosuppressive cyclosporin A analog, following traumatic brain injury. J Cereb Blood Flow Metab. 2009;29(1):87-97.
91. Mazzeo AT, Alves OL, Oilman CB, et al. Brain metabolic and hemodynamic effects of cyclosporin A after human severe traumatic brain injury: a microdialysis study. Acta Neurochir. 2008; 150(10):1019-1031.
92. Yu G, Hess DC, Borlongan CV. Combined cyclosporine-A and methylprednisone treatment exerts partial and transient neuroprotection against ischemic stroke. Brain Res. 2004;1018(1):1032-1037.
93. Kristal BS, Stavrovskaya IG, Narayanan MV, et al. The mitochondrial permeability transition as a target for neuroprotection. J Bioenerg Biomembr. 2004;36(4):309-312. (Pubitemid 39619832)
94. Neumar RW, Nolan JP, Adrie C, et al. Post-cardiac arrest sydrome. Epidemiology, pathophysiology, treatment and prognostication. Circulation. 2008;118(23):2452-2483.
95. Cour M, Loufouat J, Paillard M, et al. Inhibition of mitochondrial permeability transition to prevent the post-cardiac arrest syndrome. Eur Heart J. 2011;32(2):226-235.